Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories

Biological Psychiatry

Volumn 68, Issue 1, 2010, Pages 86-92

  Levine, Stephen Z ^a   Leucht, Stefan ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Course; early treatment response; heterogeneity; rapid response; trajectories

Indexed keywords

AMISULPRIDE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; DIAGNOSTIC USE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TIME FACTORS;

EID: 77953613795     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.01.012     Document Type: Article

References (32)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 60 (2003) 1228-1235
2. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al., American Psychiatric Association. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 161 (2004) 1-56
3. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biol Psychiatry 57 (2005) 1543-1549
4. Emsley R., Rabinowitz J., and Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 163 (2006) 743-745
5. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., and Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160 (2003) 2063-2065
6. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35 (2010) 581-590
7. Levine S.Z., and Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. [published online ahead of print October 9]. Schizophr Bull (2009)
8. Kapur S., Arenovich T., Agid O., Sajeev G., Muthen B., Chen L.C., et al. Trajectories of antipsychotic response: Moving beyond the responder/non-responder dichotomy. Schizophr Bull 35 (2009) 366-366
9. Kemmler G., Hummer M., Widschwendter C., and Fleischhacker W.W. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry 62 (2005) 1305-1312
10. Sechter D., Peuskens J., Fleurot O., Rein W., and Lecrubier Y. Amisulpride vs. risperidone in chronic schizophrenia: Results of a 6-month double-blind study. Neuropsychopharmacology 27 (2002) 1071-1081
11. Peuskens J., Bech P., Moller H.J., Bale R., Fleurot O., and Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 88 (1999) 107-117
12. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (2003) 553-564
13. Rabinowitz J., Levine S.Z., Barkai O., and Davidov O. Dropout rates in randomized clinical trials of antipsychotics: A meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 35 (2009) 775-788
14. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
15. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155 (2001) 230-233
16. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 6 (2005) 132-191
17. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 10 (1962) 790-812
18. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., and Engel R.R. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 31 (2006) 2318-2325
19. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R. Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry 187 (2005) 366-371
20. Leucht S., Davis J.M., Engel R.R., Kissling W., and Kane J.M. Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation. Acta Psychiatr Scand Suppl (2009) 7-14
21. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 162 (2005) 441-449
22. Odgers C.L., Caspi A., Broadbent J.M., Dickson N., Hancox R.J., Harrington H., et al. Prediction of differential adult health burden by conduct problem subtypes in males. Arch Gen Psychiatry 64 (2007) 476-484
23. Barker E.D., Seguin J.R., White H.R., Bates M.E., Lacourse E., Carbonneau R., et al. Developmental trajectories of male physical violence and theft: Relations to neurocognitive performance. Arch Gen Psychiatry 64 (2007) 592-599
24. Shaw P., Lerch J., Greenstein D., Sharp W., Clasen L., Evans A., et al. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 63 (2006) 540-549
25. Lacourse E., Nagin D.S., Vitaro F., Cote S., Arseneault L., and Tremblay R.E. Prediction of early-onset deviant peer group affiliation: A 12-year longitudinal study. Arch Gen Psychiatry 63 (2006) 562-568
26. Nagin D.S., and Tremblay R.E. Parental and early childhood predictors of persistent physical aggression in boys from kindergarten to high school. Arch Gen Psychiatry 58 (2001) 389-394
27. Haviland A.M., and Nagin D.S. Causal inferences with group based trajectory models. Psychometrika 70 (2005) 557-578
28. White H.R., Bates M.E., and Buyske S. Adolescence-limited versus persistent delinquency: Extending Moffitt's hypothesis into adulthood. J Abnorm Psychol 110 (2001) 600-609
29. Raftery A.E. Bayesian model selection in social research. Sociol Methodol 25 (1995) 111-163
30. Angermeyer M.C., Kuhn L., and Goldstein J.M. Gender and the course of schizophrenia: Differences in treated outcomes. Schizophr Bull 16 (1990) 293-307
31. Perkins D.O., Gu H., Boteva K., and Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 162 (2005) 1785-1804
32. Rabinowitz J., Bromet E., and Davidson M. Are patients enrolled in first episode psychosis drug trials representative of those treated in routine clinical practice?. Schizophr Res 61 (2003) 149-155